China Meheco(SH:600056) Shen Zhen Shang Bao·2026-01-22 00:43Core Viewpoint - The announcement from China Pharmaceutical regarding the acquisition of 70% of Shanghai Zezheng Pharmaceutical Technology Co., Ltd. highlights significant challenges including a sharp decline in the target company's performance, high valuation, business transformation risks, and integration difficulties [1][4]. Financial Performance - The target company is expected to see a notable decline in performance, with projected revenues of approximately 257 million yuan and 107 million yuan for 2024 and 2025 respectively, and net profits of 39.34 million yuan and -40.85 million yuan [1]. - In 2025, the target company's revenue is anticipated to drop by 31.45 million yuan to 226 million yuan, a decrease of 12.24%, while net profit is expected to plummet by 29.89 million yuan to 9.44 million yuan, a staggering decline of 75.99% [1]. - The target company is projected to achieve a significant profit of 50.29 million yuan in Q4 2025, indicating a "V-shaped recovery" with a notable "year-end rush" characteristic [2]. Business Segments - The revenue from the pharmaceutical research segment is expected to decline sharply from 131 million yuan in 2024 to 43.44 million yuan in 2025, a decrease of 66.87%, primarily due to industry pressures and reduced new orders [2]. - The target company's reliance on technology transfer for profit is increasing, with this segment accounting for 52.92% of total revenue in 2025, growing by 104.67% compared to 2024 [3]. Acquisition Justification - The valuation for the acquisition is based on an income approach, with the target company's 100% equity valued at 759 million yuan, resulting in a premium of 474 million yuan and a premium rate of 166.73% [4]. - China Pharmaceutical asserts that the valuation is cautious and reasonable, supported by the progress of ongoing projects and comparisons with industry peers [4]. Risk Management - To mitigate risks associated with the acquisition, several measures have been implemented, including staggered payments to founding shareholders and loss compensation agreements [5]. - The company has faced challenges in its own operations, with a reported revenue decline of 3.42% year-on-year for the first three quarters of 2025, and a net profit decrease of 4.64%, marking five consecutive years of decline [6].